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IL-5 is a glycoprotein secreted by activated T lymphocytes (1, 2) . cDNAs encoding
both human and mouse IL-5 were obtained (3, 4) . Purified natural or recombinant
IL-5 have been found to possess various biological activities on different cell types .
IL-5 induces the expression ofreceptors for IL-2 (5, 6) and promotes both prolifera-
tion and maturation ofmouse B lymphocytes into antibody-secreting cells (7) . To-
gether with IL-2, IL-5 supports the expression of cytotoxic functions by activated
thymocytes (2) . Also, it acts as differentiation factor for cells of the eosinophil lin-
eage from man and mice (8, 9) . The biologically active form of mouse IL-5 is an
M~ 40,000-50,000 dimer (2, 10). IL-5 binding sites displaying high (Kd 10-1 t M)
and low (10_ 9 M) affinity have been found on both BCLl tumor cells and the IL-
5-dependent B13 cell line (2, 10) . Crosslinking
[t 2sl]IL-5 to these cells has revealed
an M~ 45,000-50,000 membrane component as candidate for the IL-5-R or at least
one of its components (2, 10) . Here we describe two rat mAbs, called R52.120 and
R52.625, that recognize epitopeson the IL-5-R very close or identical to the binding
sites for IL-5 .
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Materials and Methods
Animals.
￿
BALB/c, DBA/2, C57BL/6, and C57BL/6 nu/nu mice and Lewis rats were ob-
tained from the Institute fur Biologisch Medizinische Forschung AG, Fiillinsdorf, Switzerland .
Cell Lines.
￿
The continuous proliferating cell linesCTLL (11), C4-77 (12), andFTH5 (13)
were used to assay for IL-2, IL-3, and IL-4 activities, respectively. The B cell lineage cell
lines Al, B4, B5, B,3, C2, C5, D3, IA, IB, IC, and ID were obtained from cultures in which
the LyH7 or LyD9PRO-B lymphocyte clones (14) were induced to differentiate in vitro with
bonemarrow stroma cells or splenic nonlymphoid accessory cells . These cell lines represent
intermediate stages of differentiation between the PRO-B parental clones and mature IgM'
B lymphocytes, and they express functional receptors for both IL-3 and IL-5 (R . Palacios,
unpublished observations) .
Interleukins andAssaysfor Interleukin Activity.
￿
Culture supernatants of X63-Ag-653 myelo-
macells transfected with the bovine papilloma virus-based expression vector BMGneo con-
taining cDNAs encoding mouse IL-2, -3, -4, and -5, respectively, were used as sources of
interleukins (15) .
IL-2, IL-3, and IL-4 were tested for their capacity ofsupporting growth ofIL-2-dependent
CTLL (104 cells/well), IL-3-dependent C4-77 (104 cells/well), and IL-4-dependent FTH5 (104
cells/well) cells as described in detail elsewhere (12-14) . IL-5 activity was tested by its capacity
to support growth of the IL-5-sensitive B~3 cell line . B~ 3 cells were plated at a density of 5 x
104 cells/ml in 200 ~1 culture medium (DMEM supplemented with 10% FCS, antibiotics,
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and 50 pM 2-ME) in flat-bottomed microtiter plates in the presence of different concentra-
tions of IL-5 and were incubated for 36 h at 37°C. Cell proliferation was determined by
[3H]thymidine uptake (0.5 uCi/well, sp act 5 mCi/mmol; Radiochemical Centre, Amersham,
UK) during the last 12 h of the culture period. 1 U of IL-5 was defined as the amount of
IL-5 required for half-maximal proliferation of the B13 cells. IL-5 was also tested for its ca-
pacity of promoting maturation of purified small resting C57BL/6 nu/nu splenic B cells to
IgM-secreting cells. Small resting splenic B cells were purified by velocity sedimentation as
originally described by Miller and Phillips (16). These cells were then cultured at 5 x 105
cells/ml in the presence of different amounts of IL-5. The number of IgM-secreting cells
was determined at day 5 of culture with the use of the protein A plaque assay (17).
Production of mAbs.
￿
Lewis rats were immunized on day 0 with 2 x 107 B13 cells emulsified
in CFA in the hind foot path. On day 4 and 7 the rats were boosted with 2 x 107 B13 Cells
in PBS in the same foot path. On day 8 the regional lymph nodes were removed and the
cells were fused to the azaguanine-resistant nonsecreting hybridoma cell line SP2/0. 2 x 1011
fused lymph node cells were plated in 40 microtiter plates in the presence of rat thymocytes
(3 x 106/ml) used as filler cells. Culture wells showing positive growth were tested for the
presence of antibodies able to block the IL-5-driven proliferation growth of the B13 cells as
follows: B13 cells were cultured in the presence of 5-10 U of murine IL-5 and 10% hybridoma
culture supernatant for 36 h. Proliferation of the cells was measured as described above.
For purification of the mAbs, hybridomas R52.120, R52.625, and M41 (18) were cultured
for 48-72 h in serum-free Iscove's (19) medium containing only transferrin. Antibodies were
purified from these supernatants by ion exchange over DEAE-cellulose followed by FPLC
on superose-12 (Pharmacia Fine Chemicals, Piscataway, NJ).
IL-5 Binding Assays.
￿
IL-5 was obtained from culture supernatants of X63-Ag-653 my-
eloma cells transfected with the expression vector BMG neo containing cDNA for mouse
IL-5 (15), was purified on an anti-IL-5 column (2) (a gift ofDr. K. Takatsu, Kumamoto Univer-
sity, Kumamoto, Japan), and labeled with 1251 using the Bolton and Hunter reagent (-4,000
Ci/mmol; Radiochemical Centre). IL-5 binding assays were performed as described in detail
(10). In short, B13 cells were incubated with different amounts 1251-IL-5 for 45 min at 37°C.
A 100-fold excess of unlabeled IL-5 were used to determine nonspecific bindings of 1251-IL-5.
Immunofuorescence Staining and Flow Fluorometry.
￿
For immunofluorescence studies we rou-
tinely used purified mAbs coupled to biotin. Staining of the different cell types was carried
out by incubating the cells with 1-5 tLg ofbiotinylated antibody for 30 min at 4°C. The cells
were washed once and resuspended in buffer (PBS plus 5% FCS and 0.1% NaN3) containing
an appropriate dilution of FITC-labeled Streptavidin (Amersham). Negative controls were
cells incubated with FITC-conjugated Streptavidin only. The cells were washed twice in buffer
and a third time in buffer containing propidium iodine to exclude dead cells from analysis.
Fluorescence intensity was measured with a FACScan instrument (Becton Dickinson &
Co., Mountain View, CA). A minimum of 104 cells were analyzed per sample. For cell
sorting, essentially the same staining protocol was used, with the exception that NaN3 and
propidium iodine were omitted. Fluorescence-positive cells were sorted using a FAGS 440
(Becton Dickinson & Co.) equipped with an argon laser tuned to 488 nm, operating at 200
mW power, and the gates set by forward- and side-scatter on the "lymphoid" population of
spleen cells.
Immunoprecipitation.
￿
B13 cells were cultured for 6-8 h at a density of 5 x 106 cells/ml in
methionine-free RPMI medium (Gibco Laboratories, Grand Island, NY) containing 50 Am
2-ME, antibiotics, 20 U/ml IL-5, 10% dialyzed FCS, and 100 MCi 35S-methionine/ml (sp
act >800 Ci/mmol, Amersham). Cells were washed three times in PBS and then lysed in
a buffer containing 20 mM Tris-HCI, pH 8.6, 150 mM NaCl, 5 mM MgC12, 5 mM EDTA,
10 mM NaN3, 2% NP-40, and 1 mM PMSF. The cell lysates were processed according to
a solid phase immunoprecipitation technique described byTamura et al. (20). Immunoprecipi-
tates were analyzed by SDS-PAGE (21) followed by autoradiography using X-ray films
(Kodak-X-Omat).
Results and Discussion
From the fusion of regional lymph node cells of two rats immunized with the IL-
5-R+ B13 cell line, 1,750 hybridomas were obtained. Two out of the 1,750 hybrid-omas, called R52.120 andR52.625, secreted antibodies that consistently and strongly
inhibited the proliferation of B13 cells driven by IL-5. Both R52.120 and R52.625
were cloned and subcloned by limiting dilution and both secrete a rat IgG1/u mAb.
Purified R52.120 and R52.625 mAbs inhibited the action of IL-5, so that 1 /4g/ml
of either antibody suppressed by 60-70% the proliferation of B13 cells promoted
by 5 U of IL-5 (Fig. 1 D). Neither antibody, even at a concentration as high as 20
hg/ml, had any effect on the proliferation driven by as little as 1 U of IL-2 or IL-4,
on their respective target cells (Fig. 1, A and C). Similarly, the mAbs did not inhibit
the IL-3-induced proliferation of three IL-3-reactive cell lines (illustrated with one
example in Fig. 1 C). A special case is the B13 cell line, used to produce the IL-
5-Rspecific mAbs R52.120 and R52.625, which respond to both IL-3 and IL-5. High
concentrations (20 ug/ml) ofboth mAbs inhibited by 50% the proliferative response
to IL-3. The inhibitory effect of the antibodies on the IL-3-driven response of B13
cells but not of the other IL-3-sensitive cell lines might indicate an interesting con-
nection of the IL-3 and IL-5 responsiveness and, therefore, of the corresponding
receptors on B13 cells.
Next we tested R52.120 and R52.625 mAbs for theircapacity of inhibiting binding
of radiolabeled IL-5 to B13 cells. The target cells incubated with [125]IL-5 and a 100-
fold excess of unlabeled IL-5 was used to determine nonspecific binding of [125I]IL-
5; the isotype-matched rat anti-mouse IgM mAb M41 (16) was used as negative
control antibody in these experiments. The results (Fig. 2) show that both R52.120
and R52.625 mAbs blocked the specific binding of radiolabeled IL-5 to B13 cells.
1 jug/ml of either antibody inhibited by >40% the binding of IL-5 to B13 cells. No
inhibition ofthe IL-5 bindingto these cellswas observed with the irrelevant isotype-
matched control antibody (Fig. 2). Moreover, neither R52.120 nor R52.625 mAbs
blocked the binding of [1251]transferrin to the same B13 Cells. We conclude that the
mAbs R52.120 and R52.625 react against the IL-5-R and that the epitopes recog-
nizedby them in thereceptorsmust be very close or identical to the IL-5 bindingsites.
Thenext set ofexperiments was performed to studyby immunofluorescence staining
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FIGURE 1.
￿
mAbs R52.120 and R52.625 in-
hibit the action of IL-5 but not the action of
IL-2, IL-3, or IL-4. Different concentrations
ofpurified R52.120 (")andR52.625 (O)were
addedto thecultures setup forassessing their
capacity ofinhibiting the action of IL-2, IL-
3, IL-4, and IL-5 in the following cell re-
sponses. (A)Proliferation ofCTLLcells driven
by rIL-2 (3 U/ml); (B)proliferation of C4-77
cellssupportedby rIL-3(5 U/ml);(C)prolifer-
ation of FTH5 cells promoted by rIL-4 (5
U/ml); and (D) proliferation of B 13 cells
driven by rIL-5(25U/ml). In theexperiments
shown above, the [3H]thymidine uptake of
target cellscultured in theirrespective growth
factors wasas follows: CTLL, 11.600 cpm; C4-
77, 12.400 cpm; FTH5, 14.300 cpm; and 1313,
21.000 cpm. The [3H]thymidine uptake of
the different target cells cultured in medium
2.5 5 110 20
￿
2.5 5 to 20
￿
withoutgrowth factors wasas follows: CTLL,
tlglml of mab added
￿
220 cpm; C4-77, 160cpm; FTH5, 190 cpm;
and 1313, 250 cpm.
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and flow fluorocytometry (FAGS) the binding of both R52.120 and R52.625 mAbs
to our collection of nontransformed IL-5-sensitive B cell lineage cell lines, as well
as the presence of positive cells among nucleated cells freshly isolated from several
hematolymphoid tissues from normal BALB/c, DBA/2, and C57BL/6 mice. Both
R52.120 and R52.625 mAbs bound to all 12 B cell lineage cell lines known to grow
in IL-5, as illustrated in Fig. 3, A and B with the data obtained with two such cell
lines. Between 2% and 4% spleen cells from all three strains studied were positive
for both R52.120 and R52.625 mAbs, but no positive cells could be detected in the
adult thymus and lymph nodes (Fig. 3 C and data not shown). About 5% of LPS-
activated splenic B cells bound R52.120 and R52.625 mAbs, while no binding was
observed to Con A-activated splenic T cells. Bone marrow nucleated cells gated for
lymphoid cells (by forward- and side-scatter) contained N5% positive cells for both
antibodies (Fig. 3D), and marrow cellsgated formyeloid/granulocytes (alsoby forward-
Control R52.120 R52.625
FIGURE 2.
￿
R52.120 and R52.625 inhibit the binding of
1211-
IL-5 to B13 cells. B13 cellswere incubated for30 min at 37°C
with 40,000 cpm 1251-IL-5 (35 U) in the presence of different
concentrations ofpurified R52.120 (0), R52.625 (0), andM41
(A). The amount ofradioactivity (cpm)bound in theabsence
of antibodies was 2,600 and in thepresence of 100-fold excess
of nonlabeled IL-5 was 240.
FIGURE 3.
￿
Binding of R52.120 and R52.625 mAbs
usingimmunofluorescence staining andflow fluoro-
cytometry to the following cell lines or freshly iso-
lated cell populations. (A) B13 cells, (B) LyH7 cells,
(C)BALB/c spleen cells, (D)BALB/c bone marrow
cellsgatedby forward- andside-scatter forthe"lym-
phoid" population, and (E) BALB/c bone marrow
cellsgatedby forward- and side-scatter forthe"my-
eloid/granulocyte" population.ROLINK ET AL.
￿
1697
and side-scatter) had 10-1517o positive cells forboth R52.120 andR52.625 mAbs (Fig.
3 E). Peritoneal cellswere also found to contain N10-14% cells that bind both anti-
bodies.
Previous studies have shown that IL-5 promotes maturation of B lymphocytes
into antibody-secreting cells (PFC) (7). In light of the finding that both R52.120
and R52.625 mAbs consistently bound to 2-4% lymphoid splenocytes, we wished
to know whether among these cells would be B cells responsive to IL-5. Thus,
R52.120 + lymphoid splenocytes were isolated by cell sorter and tested for their ca-
pacity to mature into antibody-secreting cells (PFC) in the presence of IL-5. Table
I summarizes the results of four experiments. It shows that the frequency of IL-
5-inducible PFC increased by a factor of 15-20 in the R52.120' cell sorter-purified
population as compared with that observed in the unsorted population (Table I).
In fact, the frequency of PFC in purified R52.120+ spleen cells stimulated by IL-5
was similarto that obtained with thesecells in thecultures stimulated by LPS(Table
I). We conclude that among the R52.120' spleen cells, there are B lymphocytes able
to mature into antibody-producing cells upon exposure to IL-5.
Yet another piece of experimental evidence for the existence of IL-5-reactive B
lymphocytes in mouse spleen is the experiment in whichboth R52.120 and R52.625
mAbs inhibited the IL-5-induced maturation of spleen cells to IgM-secreting cells
(Table II). These types of experiments were performed with small, resting spleen
cells purified by velocity sedimentation (16). However, since the population of IL-
5-reactive B cells is small, we cannot completely exclude that some of the B cells
that respond to IL-5 in this system have been preactivated in vivo. In the same ex-
periment these mAbs did not inhibit the IL-2-induced maturation of the spleen B
cells, while anti-IL-2-R mAbs did (Table II).
We have begun the biochemical characterization of the antigens recognized by
the R52.120 and R52.625 mAb. These antibodies arelikely to interact with the same
or with sterically close epitopes on the IL-5-R as they block each other's binding
to B13 cells. We found that both antibodies specifically precipitate from cell lysates
of "S-methionine-labeled B13 cells three proteins with apparent Mr of 46,000,
130,000, and 140,000 under reducing (Fig. 4) andnonreducingconditions (not shown),
indicating that the three proteins are not linked by disulfide bridges. Similarresults
were obtained with another cell line that binds R52.120 and R52.625 mAbs (not
TABLE I
Precursor Frequencies of IL-5- and LPS-inducible IgM-Producing Cells
in Total and R52.120+ Spleen Cells
The precursor frequencies of IL-5- andLPS-inducible IgM-secreting cells were
determined as described (7). The percentage ofpositively sorted cells with mAb
R52.120 varied from 1 .5% to 2.5 %. The results are the range ofthe frequen-
cies obtained in four experiments.
Precursor frequency of:
IL-5-inducible LPS-inducible
Spleen cells IgM-secreting cells IgM-secreting cells
R52.120` 1 :4-1 :12 1 :5-1:15
Total 1 :60-1 :200 1 :11-1 :181698
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TABLE II
R52.120 and R52.625 mAbs Block the IL-5-driven but not
the IL-2-induced Maturation of Small Resting C57BL/6
nu/nu Splenic B Cells to Antibody-secreting Cells
Small resting B cells (at a concentration of 5 x 105 cells/ml) were stimulated
with 100 U/ml IL-2 or 5 U/ml IL-5 . IgM-secreting cells were determined at
day 5 of culture as described (7) .
* The mAbs R52.120 and R52 .625 (10,ug/ml) and the anti-IL-2-R antibodies
(23, 24) (final concentration 10% hybridoma culture supernatant) were ad-
ded at the beginning of the cultures .
t IgM-PFC/105 plated cells .
shown) . The immunoprecipitations of cell lysates from surface 1251-labeled B13 cells
have not yet yielded an identifiable labeled protein, perhaps due to destruction of
the R52.120 and R52.625 antigens by the iodination or because the proteins recog-
nized by the mAbs are not efficiently iodinated .
The binding of radiolabeled IL-5 to its receptor followed by crosslinking of this
complex have so far revealed only a single IL-5 binding protein ofM r45,000-50,000
(2, 10) . On the basis of these molecular weight analyses, it is tempting to speculate
that the IL-5 binding protein corresponds to theM r 46,000 molecule recognized
by mAbs R52.120 and R52.625 .
Our knowledge of the binding of IL-5 and the nature of the receptor identified
by either IL-5 binding or mAb binding leaves us with at least two possible models
for the IL-5-R . In the first model the IL-5-R is a complex of three proteins with
Mr 45,000-50,000, 130,000, and 140,000, in whichMr 45,000-50,000 is the only
IL-5 binding protein andM r 130,000 and 140,000 are possibly involved in signal
transduction . Since IL-5 is biologically active only in its dimeric form (2, 10), low
affinity binding would be the binding of IL-5 to one of these protein complexes,
FIGURE 4 .
￿
Biochemical characterization by SDS-PAGE of the an-
tigen recognized by R52.120 and R52.625 mAbs. The cell lysates from
35S-methionine-labeled B13 cells were subjected to immunoprecipi-
tation with control M41 (laneA), R52.120 (lane B), and R52.625 (lane
C) antibodies . The autoradiogram represents a 10% gel, run under
reducing conditions .
Antibodies added
to cultures*
B cell
IL-2
response stimulated by :
IL-5
None 380 : 425
R52 .120 420 38
R52 .625 360 47
PC61 + 7134 25 410ROLINK ET AL.
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whereas high affinity IL-5 binding would represent the crosslinking of two of these
complexes.
The finding that the monomeric biologically inactive form of IL-5 binds to the
IL-5-R complex with low affinity and can blockthe high affinity binding ofthe dimeric
form of IL-5 (unpublished results) supports this M, 45,000-50,000 homodimer
binding model.
The second model would be that the IL-5-R is a "hetero"protein complex in which
M, 45,000-50,000 is the IL-5 binding protein giving rise to only low affinity
binding. For high affinity binding the IL-5 should have to interact with a second
protein, maybe with M, 130,000 and/or 140,000 . This second model would be com-
parable with the model for the IL-2-R. In the case of the IL-2-R, it is known that
the presence ofboth p70 and p55 are necessary for binding of IL-2 with high affinity;
p55 alone binds IL-2 with low affinity, while p70 alone binds it with intermediate
affinity (22). Thus far, a second IL-5 protein has not yet been identified, and in
particular, IL-5 binding to the M, 130,000 or 140,000 proteins has not yet been ob-
served.
Ultimate proof for the nature of the IL-5-R will have to come from cloning of
the genes encoding this receptor and subsequent functional tests by transfection ex-
periments. The availability of monoclonal anti-IL-5-R antibodies and cell lines ex-
pressing high levels of IL-5-R with capacity ofunlimited growth should now greatly
facilitate this cloning as well as the study ofthe mechanism of action and the biolog-
ical relevance of IL-5.
Summary
The rat mAbs R52.120 and R52.625 inhibit the action of IL-5 on both IL-5-sensitive
cell lines and freshly isolated splenic B lymphocytes. Neither antibody inhibits the
proliferative cell responses promoted by IL-2, IL-3, or IL-4. Purified R52.120+ lym-
phoid spleen cells contain 15-20-fold higher numbers of B lymphocytes responding
to IL-5 in the form ofmaturationinto antibody-producing cells. By immunofluores-
cence staining and flow fluorocytometry, the R52 .120 and R52.625 antibodies bound
to all 12 IL-5-sensitive cell lines tested. Both antibodies react with 2-4% cells in
the spleen, 517o lymphoid cells, and 10-1517o myeloid cells in the bone marrow, and
10-14% in the peritoneum of C57BL/6, DBA/2, and BALB/c adult mice. No posi-
tive cells for either antibody were detected in the thymus and lymph nodes of these
mice. Both R52.120 and R52.625 antibodies specifically inhibit the binding of ra-
diolabeled IL-5 to its receptor. Finally, R52 .120 and R52 .625 antibodies precipitate
from 15S-methionine-labeled IL-5-R` cell lysates three proteins with M, 46,000,
130,000, and 140,000. Taken together from these results, we conclude that the R52 .120
and R52 .625 mAbs recognize epitopes on the IL-5-R complex very close or iden-
tical to the IL-5 binding sites.
We thank K. Takatsu (Kumamoto University Medical School,Japan) for the gift of the anti-
IL-5 column, Diana Thorpe for help with FAGS analysis, Annick Peter for able technical
assistance, and Florence Mori for typing the manuscript.
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